Australia’s Therapeutic Goods Administration (TGA) approved Niktimvo (axatilimab) for chronic graft-versus-host disease (cGVHD) in May 2026, making Australia the first market outside the US to authorize the therapy. The decision strengthens the role of macrophage-targeted treatments for heavily pretreated patients, while highlighting reimbursement, real-world adoption, and earlier-line evidence as key factors shaping its long-term clinical and commercial potential, says GlobalData, a leading intelligence and productivity platform.

Graysen Vigneux, Immunology Analyst at GlobalData, comments: “Niktimvo’s macrophage-directed mechanism is differentiated from the existing therapies and is particularly relevant to a disease driven by persistent inflammation and fibrosis across multiple organs.”

The approval was supported by the pivotal Phase II AGAVE-201 trial. At the approved dose of 0.3 mg/kg intravenously every two weeks, the overall response rate was 74% (95% CI: 63%-83%). The company also reported that 60% of responding patients remained alive without requiring new systemic treatment for at least 12 months after their initial response.

The Australian approval addresses a meaningful post-transplant burden. According to Specialised Therapeutics, approximately 600 allogeneic transplants are performed annually in Australia, and cGVHD affects an estimated 40%-50% of recipients. However, the addressable population for Niktimvo will be narrower because it is restricted to patients who have already failed at least two systemic treatment lines.

Vigneux adds: “A high response rate in a heavily pretreated population is encouraging, but the open-label, non-comparative study design means the results should not be used for direct efficacy comparisons with other cGVHD therapies. Clinicians will also consider organ-specific responses, symptom improvement, durability, safety, and treatment burden.”

Vigneux notes: “TGA registration is an important regulatory milestone, but broad uptake will depend on reimbursement. Niktimvo was not listed on the Pharmaceutical Benefits Scheme when the approval was announced, so a positive funding pathway will be central to equitable access and commercial adoption in this small, high-need population.”

Niktimvo is also being evaluated in earlier-line combination studies with ruxolitinib and with corticosteroids. These programs could expand its future role, but randomized evidence will be needed to establish whether CSF-1R blockade improves outcomes when used earlier in the treatment pathway.

Vigneux concludes: “The approval gives Australian clinicians a novel option for difficult-to-treat cGVHD and validates macrophage targeting as a therapeutic strategy. Near-term uptake will be shaped by PBS reimbursement, practical infusion requirements, and how Niktimvo is positioned relative to established later-line therapies.”